# Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease

> **NCT06117423** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University Medical Center Groningen** · enrollment: 21 (estimated)

## Conditions studied

- Crohn Disease
- Ulcerative Colitis

## Interventions

- **DRUG:** Adalimumab-680LT
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT06117423
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06117423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06117423, "Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06117423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*